Hormone Treatments for Men With Prostate Cancer Could Increase Health Risks
Today the FDA reported that it was examining data from several different studies to determine if the risks with commonly used Hormone treatment for prostate cancer Gonadotropin-Releasing Hormone. Recent findings hint that certain hormone treatments for men with prostate cancer pose greater risk for diabetes or heart trouble.
Products under investigation are: Lupron, Zoladex, Trelstar, Vantas, Eligard and Synarel.
According to Reuters, the agency said it has not made any conclusions about GnRH agonists but that patients should be monitored for potential onset of diabetes or cardiovascular disease that can result in heart attacks, stroke and sudden cardiac death.
Tweet
